Bioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical Labs

Bioptimus (TXG) launched STELA, a multinational spatial biology atlas anchored by partnerships with 10x Genomics and Broad Clinical Labs.

Rhea-AI Summary

Bioptimus (TXG) launched STELA, a multinational spatial biology atlas anchored by partnerships with 10x Genomics and Broad Clinical Labs. STELA aims to profile up to 100,000 patient specimens (~20x current scale) across oncology and immunology, integrating Xenium spatial transcriptomics, multi-omics, histopathology imaging, and longitudinal clinical data across the US, Europe, and Asia.

STELA will feed Bioptimus' M-Optimus foundation model, standardizing data generation, harmonized processing, and AI-driven quality control to enable large-scale, reproducible datasets for translational research and therapeutic discovery.

Positive

• Profile up to 100,000 specimens (~20x existing atlases)
• Partnership with 10x Genomics Xenium for standardized spatial transcriptomics
• Multi-year collaboration with Broad Clinical Labs for industrial-scale data production
• Data generation across three continents (US, Europe, Asia)

Negative

• Initial scope limited to oncology and immunology, excluding other indications at launch
• Multi-year agreement and initiative lack disclosed financial or commercial terms

Argus Mar 25 session

+5.55% close to close Open Argus

Details

News Market Reaction – TXG

On Mar 25, the day this news came out, TXG closed 5.55% above the previous close.

Data tracked by StockTitan Argus for the Mar 25 session.

Market Context

On Mar 25, the day this news came out, the stock closed 5.5% above the previous close. A strong posi...

Analysis

On Mar 25, the day this news came out, the stock closed 5.5% above the previous close. A strong positive reaction aligns with TXG’s role in large, AI-ready biological datasets. The STELA announcement reinforces prior themes seen in the PerturbAI CRISPR atlas and earlier Xenium partnerships. With shares at $19.81, still below the $23.56 52-week high and above the $15.46 200-day MA, investors have previously rewarded similar data- and AI-focused collaborations, though recent insider net selling and ongoing ownership shifts from institutional holders add an additional layer of risk awareness.

Key Figures

Planned specimen count: up to 100,000 patient specimens Scale increase: ~20-fold increase Continents covered: three continents +5 more

Planned specimen count

up to 100,000 patient specimens

Scale of STELA spatial biology atlas

Scale increase

~20-fold increase

Increase over existing spatial biology atlases

Continents covered

three continents

United States, Europe, and Asia participation in STELA

2025 revenue

$642.8M

Full-year 2025 revenue (prior earnings release context)

Q4 2025 revenue

$166.0M

Fourth quarter 2025 revenue

Non-recurring litigation revenue

$44.1M

Included in 2025 revenue, previously disclosed

2026 revenue guidance

$600M–$625M

Company outlook for 2026 revenue

Current price

$19.81

Price before STELA announcement, up 3.5% on the day

Historical Context

5 past events · Latest: Mar 17

5 events

1. Mar 17

   CRISPR atlas partnership

   24h Move

   +8.4%

   PerturbAI unveils 8 million–cell in vivo CRISPR atlas using TXG tech.

2. Feb 19

   Conference participation

   24h Move

   -1.6%

   Management schedules fireside chat at TD Cowen health care conference.

3. Feb 12

   Earnings results

   24h Move

   +3.5%

   Q4 and FY2025 results with $642.8M revenue and narrowed losses, plus 2026 guidance.

4. Feb 4

   AI cancer partnership

   24h Move

   -1.1%

   PharosAI collaboration to build large multimodal cancer dataset on Xenium platform.

5. Jan 22

   Earnings date set

   24h Move

   -3.5%

   Company schedules Q4 and FY2025 earnings release and investor call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

spatial biology, spatial transcriptomics, multi-omics, genomics, +4 more

8 terms

spatial biology medical

"Broad Clinical Laboratories to support STELA via the generation of spatial biology data at scale."

Spatial biology maps where different cells and molecules sit inside tissues, like a detailed city map showing not just who lives in a neighborhood but where every house and shop is located. For investors, those location details can reveal how diseases start and respond to treatments, guiding new drugs, diagnostics, and lab tools that can change clinical success rates and create commercial opportunities.

spatial transcriptomics medical

"Leveraging the Xenium spatial transcriptomics platform as the foundational partner for the launch"

Spatial transcriptomics is a lab technique that measures which genes are active and where they are active inside a tissue sample, producing a “map” of cell behavior rather than a single averaged reading. For investors, this matters because those maps can reveal precise disease mechanisms, identify better drug targets, and improve diagnostic tests — potentially speeding development, reducing trial failures, and creating new commercial opportunities in biotech and diagnostics.

multi-omics medical

"designed to generate harmonized multi-omics patient data."

Multi-omics is a comprehensive approach that combines different types of biological data—such as genetic information, proteins, and other molecules—to gain a detailed understanding of how living systems function. For investors, this approach can reveal insights into health, disease, or biological processes that may influence the development of new treatments or technologies, potentially impacting market opportunities and innovation in healthcare.

genomics medical

"multi-omics data (e.g., genomics, transcriptomics and proteomics), with longitudinal clinical records."

The study of an organism’s complete set of genes and how those genes behave, interact, and influence traits — like reading and interpreting a living organism’s instruction manual. For investors, genomics matters because it drives new drugs, diagnostics and personalized treatments that can create big commercial opportunities or regulatory risks; understanding genomics helps assess a company’s technology edge, market potential and long-term value.

transcriptomics medical

"multi-omics data (e.g., genomics, transcriptomics and proteomics), with longitudinal clinical records."

Analysis of all the RNA molecules a cell produces, showing which genes are actively being used at a given time—like reading which recipes are being pulled from a cookbook to see what’s actually being cooked. For investors, transcriptomics helps reveal how diseases work, whether a drug is hitting its target, and which patient groups are most likely to benefit, making it a tool for valuing therapies, guiding clinical trials, and spotting diagnostic or therapeutic opportunities.

proteomics medical

"multi-omics data (e.g., genomics, transcriptomics and proteomics), with longitudinal clinical records."

Proteomics is the large-scale study of all the proteins produced by a cell, tissue or organism, like taking a full inventory and watching how the workforce and machines inside a factory behave. For investors, proteomics matters because it helps identify drug targets, disease indicators and responses to treatments—information that can speed development, reduce risk, guide partnerships and reveal new commercial opportunities in biotech and diagnostics.

histopathology medical

"integrating: high-resolution spatial transcriptomics, matched histopathology imaging, multi-omics data"

Microscopic examination of tissue samples to identify disease, damage, or the effects of a treatment; pathologists slice, stain and study cells much like a mechanic inspects engine parts to find what’s broken. For investors, histopathology provides hard evidence about whether a drug, device or diagnostic actually works or causes harm, and those findings can strongly influence clinical outcomes, regulatory decisions and a company’s future value.

foundation model technical

"large-scale AI foundation model development, bringing together complementary capabilities"

A foundation model is a large artificial intelligence system trained on vast, diverse data so it can be adapted to many tasks—like a universal engine that can be tuned to drive different products or services. Investors care because these models can lower the cost and time to build new AI-enabled offerings, create competitive advantages or concentration risks, and drive capital needs for compute, talent and regulation that affect company value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The global initiative aims to profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing a ~20x increase in scale over existing data available in the world today

• The Launch of STELA: Bioptimus is establishing the largest clinically linked multimodal atlas, starting in oncology and immunology tissue, designed to generate harmonized multi-omics patient data.
• A Strategic Partnership with 10x Genomics: Leveraging the Xenium spatial transcriptomics platform as the foundational partner for the launch, the initiative sets a new benchmark for reproducible, AI-ready data generation across leading research institutions worldwide.
• A Strategic Partnership with the Broad Clinical Labs: A multi-year agreement with Broad Clinical Laboratories to support STELA via the generation of spatial biology data at scale.
• Profiling Up to 100,000 Patient Specimens: Representing a ~20-fold increase in scale over existing spatial biology atlases, STELA will integrate spatial technologies, pathology imaging, multi-omics, and longitudinal clinical data across three continents.

PARIS, March 25, 2026 /PRNewswire/ -- Bioptimus, a global AI company building the world's first world model for biology, today announced the launch of its Spatial Tissue Embedding Learning Atlas (STELA), a multinational spatial data generation initiative anchored by a partnership with 10x Genomics, Inc. (Nasdaq: TXG) and Broad Clinical Labs.

While foundation models for language have thrived on vast digital datasets, biology has long lacked the standardized, high-quality data scale required for a similar breakthrough, particularly for clinical data; Bioptimus is closing this gap by building the data infrastructure necessary to power M-Optimus, the first multimodal and multiscale world model of biology. STELA will serve as the data backbone for M-Optimus, generating massive datasets designed to decrypt the complex organization of human tissues. M-Optimus will leverage this massive multimodal repository to map how molecular and cellular interactions drive disease in fields like oncology and inflammation, ultimately allowing researchers to anticipate patient responses to novel therapies, accelerate drug development, and design more effective immunotherapies.

Starting with 10x Genomics'' Xenium spatial transcriptomics and designed to integrate additional spatial and molecular profiling technologies over time, STELA will generate harmonized datasets, integrating: high-resolution spatial transcriptomics, matched histopathology imaging, multi-omics data (e.g., genomics, transcriptomics and proteomics), with longitudinal clinical records. The initiative aims to profile up to 100,000 patient tissue specimens across three continents: the United States, Europe, and Asia, establishing the world's largest clinically linked, spatially profiled, multimodal patient data atlas.

Participating hospitals and research institutions will contribute samples under standardized protocols and, in return, receive access to rich spatial characterization and foundation model capabilities. This collaboration empowers clinicians to turn raw data into actionable insights through more precise diagnostic and therapeutic strategies. By aligning data generation protocols, data processing and storage, and AI model development within a unified framework at a diverse, global scale, STELA establishes foundational infrastructure for the next era of biological AI.

"Today, most patients' diagnostic data is used to inform decisions for only that individual. We envision a world where every patient can contribute insights to better inform the care and treatment outcomes of future patients; just as patients with other diseases, other heritage and even from the past are informing their treatment," said Jean Philippe Vert, PhD, Co-Founder and CEO of Bioptimus. "STELA is the fuel to power M-Optimus, allowing us to map the intricate interactions between cells and tissues, across indications, at unprecedented scales, unlocking a new era of precision medicine."

Industry-Shaping Partnerships

The collaboration between Bioptimus and 10x Genomics aligns advanced spatial biology technologies with large-scale AI foundation model development, bringing together complementary capabilities to reshape how biomedical data is generated and applied. Using the Xenium platform, STELA will generate highly standardized spatial datasets across participating institutions worldwide, enabling the large-scale, reproducible data generation required for large-scale AI model development.

"Many of the most important questions in medicine come down to understanding how cells interact within complex human tissues," said Serge Saxonov, Chief Executive Officer and Co-founder of 10x Genomics. "By enabling spatial profiling at unprecedented scale, STELA will generate foundational datasets that allow researchers to connect the underlying biology with disease outcomes, unlocking new insights that can accelerate and improve therapeutic discovery and development."

Bioptimus will anchor its STELA initiative through a landmark collaboration with the Broad Clinical Laboratories, bridging industrial-scale data generation with frontier AI research. This partnership leverages Broad's high-throughput spatial biology capabilities to process biological samples at scale, creating a massive-scale repository of high-resolution spatial transcriptomics data. Beyond data production, the two organizations will co-develop next-generation, AI-driven quality control metrics and predictive tools designed to optimize assay performance and automate biological insights. By integrating Bioptimus's proprietary AI models with Broad's world leading laboratory workflows, this collaboration ensures that the STELA initiative is built on a foundation of unprecedented technical precision, accelerating the development of transformative AI models for the life sciences.

"To unlock the true clinical potential of spatial biology, we must pair massive-scale data generation with uncompromising data quality," Niall Lennon, Chief Scientific Officer of Broad Clinical Labs added. "By combining our high-throughput laboratory workflows with Bioptimus's advanced AI, we are co-developing next-generation quality control metrics that ensure the highest data integrity. This unprecedented technical precision guarantees that the insights generated by STELA can be confidently translated into actionable clinical diagnostics and precision therapies."

About Bioptimus

Bioptimus is a global AI biotech company pioneering the world's first universal foundation model for biology. By combining cutting-edge AI with massive, multimodal, proprietary data generation, Bioptimus is building a unifying framework that connects all scales of biology, from molecules to patients, delivering interpretable, dynamic, and actionable insights. M-Optimus-1 represents the first World Model of Biology. H-Optimus, the foundation model of human histology has over 1 million downloads, and is an industry-leading model being adopted across research, drug discovery, and clinical pipelines. Bioptimus models are in use by 16 of the top 20 pharmaceutical companies.

For more information about Bioptimus, visit: www.bioptimus.com

Media Contact:

press@bioptimus.com

About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

View original content to download multimedia:https://www.prnewswire.com/news-releases/bioptimus-announces-stela-the-worlds-largest-clinically-linked-spatial-biology-atlas-alongside-key-partners-10x-genomics-and-broad-clinical-labs-302724250.html

SOURCE Bioptimus

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is STELA announced by Bioptimus (TXG) on March 25, 2026?

STELA is a multinational spatial biology atlas designed to generate harmonized multimodal patient data at large scale. According to Bioptimus, it will profile up to 100,000 specimens using Xenium spatial transcriptomics, multi-omics, imaging, and clinical records across three continents.

How does 10x Genomics (TXG) participate in Bioptimus's STELA initiative?

10x Genomics provides the Xenium spatial transcriptomics platform as the foundational technology for STELA. According to 10x Genomics, Xenium will enable standardized, high-resolution spatial datasets to support reproducible AI-ready data generation worldwide.

What role does Broad Clinical Labs play in STELA with Bioptimus (TXG)?

Broad Clinical Labs will support industrial-scale processing and spatial data production for STELA. According to Broad Clinical Labs, the multi-year collaboration includes high-throughput workflows and co-development of AI-driven quality control metrics for assay performance.

How large is STELA compared with existing spatial biology atlases?

STELA targets about a 20-fold increase in scale over current atlases by profiling up to 100,000 specimens. According to Bioptimus, this scale aims to create the world's largest clinically linked multimodal spatial patient data atlas.

Which diseases and geographies will STELA initially cover under Bioptimus (TXG)?

STELA will start with oncology and immunology tissue and collect samples across the United States, Europe, and Asia. According to Bioptimus, participating hospitals will follow standardized protocols and gain access to harmonized spatial and clinical datasets.

Will STELA provide immediate commercial returns or financial terms for investors in Bioptimus (TXG)?

The announcement does not disclose commercial revenue targets or financial terms for the partnerships and agreement. According to Bioptimus, the focus is on data generation, harmonization, and powering the M-Optimus foundation model rather than immediate financial metrics.